New study tracks xarelto safety in infants with blood clots
NCT ID NCT05900388
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study will collect data from health records of 850 children under 2 years old who have venous thromboembolism (blood clots). The goal is to see how doctors prescribe rivaroxaban (Xarelto) and other standard blood thinners, and to track any serious bleeding. No new treatments or tests are given—researchers simply analyze existing information from national health databases in Denmark, Sweden, France, and Spain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rivaroxaban (Xarelto) oral suspension
What this could lead to
If successful, this study could provide better information on how rivaroxaban is used and how safe it is in very young children with blood clots.
What could go wrong
This is an observational study that only looks at existing data, so it cannot prove cause and effect. Results may be limited by the quality of the records and may not apply to all children.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Many locations
Multiple Locations, Denmark
-
Many locations
Multiple Locations, France
-
Many locations
Multiple Locations, Spain
-
Many locations
Multiple Locations, Sweden